Comparison of the antiangiogenic activity of modified rgdrgdendostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model

Molecular Vision

Volumn 17, Issue , 2011, Pages 1918-1928

  Ge, Hong yan ^a   Xiao, Nan ^a   Yin, Xiu li ^a   Fu, Song bin ^b   Ge, Jin ying ^a   Shi, YanfPostepy Hig Med Dosw ^a   Liu, Ping ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ARGINYLGLYCYLASPARTYLARGINYLGLYCYLASPARTIC ACID ENDOSTATIN; ENDOSTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AQUEOUS HUMOR; ARTICLE; COMPARATIVE STUDY; CONJUNCTIVA; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; SITE DIRECTED MUTAGENESIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; BASE SEQUENCE; CORNEA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOSTATINS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAOCULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960729301     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Yoon KC, Ahn KY, Lee JH, Chun BJ, Park SW, Seo MS, Park YG, Kim KK. Lipid-mediated delivery of brain-specific angiogenesis inhibEndostatin inhibits VEGFitor 1 gene reduces corneal neovascularization in an in vivo rabbit model. Gene Ther 2005; 12:617-24.
2. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001; 12:242-9.
3. Benelli U, Ross JR, Nardi M, Klintworth GK. Corneal neovascularization induced by xenografts or chemical cautery: Inhibition by cyclosporin A. Invest Ophthalmol Vis Sci 1997; 38:274-82.
4. Hayashi A, Popovich KS, Kim HC, de Juan E. Role of protein tyrosine phosphorylation in rat corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997; 235:460-7.
5. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43:245-69.
6. Zhang P, Wu D, Ge J, Zhu Z, Feng G, Yue T, Lin J, Zheng H. Experimental inhibition of corneal neovascularization by endostatin gene transfection in vivo. Chin Med J (Engl) 2003; 116:1869-74.
7. Peyman GA, Kivilcim M, Morales AM, DellaCroce JT, Conway MD. Inhibition of corneal angiogenesis by ascorbic acid in the rat model. Graefes Arch Clin Exp Ophthalmol 2007; 245:1461-7.
8. Dueñas Z, Torner L, Corbacho AM, Ochoa A, Gutiérrez-Ospina G, López-Barrera F, Barrios FA, Berger P, Martínez de la Escalera G, Clapp C. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest Ophthalmol Vis Sci 1999; 40:2498-505.
9. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120:1063-8.
10. Joussen AM, Beecken WD, Moromizato Y, Schwartz A, Kirchhof B, Poulaki V. Inhibition of inflammatory corneal aniogenensis by TNP-470. Invest Ophthalmol Vis Sci 2001; 42:2510-6.
11. Phillips K, Arffa R, Cintron C, Rose J, Miller D, Kublin CL, Kenyon KR. Effect of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983; 101:640-3.
12. Du Z, Hou S. The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 2003; 170:2000-3.
13. Lopez ES, Rizzo MM, Croxatto JO, Mazzolini G, Gallo JE. Suramab, a novel antiangiogenic agent, reduces tumor growth and corneal neovascularization. Cancer Chemother Pharmacol 2011; 67:723-8.
14. Hosseini H, Mahmood N. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses 2007; 68:799-801.
15. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48:2545-52.
16. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007; 245:1577-9.
17. Sharma A, Bettis DI, Cowden JW, Mohan RR. Localization of angiotensin converting enzyme in rabbit cornea and its rolein controlling corneal angiogenesis in vivo. Mol Vis 2010; 16:720-8.
18. Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ, Kovesdi I, Rakoczy PE. Inhibition of angiogenesis by daenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12:1299-310.
19. Murthy RC, McFarland TJ, Yoken J, Chen S, Barone C, Burke D, Zhang Y, Appukuttan B, Stout JT. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44:1837-42.
20. Zuo L, Fan Y, Wang F, Gu Q, Xu X. A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization. Curr Eye Res 2010; 35:375-84.
21. Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 2005; 11:28-35.
22. Chen P, Yin H, Wang Y, Mi J, He W, Xie L, Wang Y. Multigene targeted antiangiogenic therapies for experimental corneal neovascularization. Mol Vis 2010; 16:310-9.
23. Plum SM, Hanson AD, Volker KM, Vu HA, Lee BK, Fogler WE, Fortier AH. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. Clin Cancer Res 2003; 9:4619-26.
24. Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20:3804-14.
25. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-85.
26. Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H, Khattar P, Mishal Z, Perricaudet M, Li H. Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 2003; 14:997-1008.
27. Lai LJ, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci 2007; 14:313-22.
28. Nicosia RF, Bonanno E. Inhibition of angiogenesis in vitro by Arg-Gly-Asp-containing synthetic peptide. Am J Pathol 1991; 138:829-33.
29. Hill-Bator A, Opolski A. Biological activity of synthetic analogs of laminin active sequences: YIGSR, RGD, SIKVAV. Postepy Hig Med Dosw 2002; 56:579-88.
30. Koh JT, Lee ZH, Ahn KY, Kim JK, Bae CS, Kim HH, Kee HJ, Kim KK. Characterization of mouse brain-specific angiogenesis inhibitor 1 (BAI1) and phytanoyl-CoA alphahydroxylaseassociated protein 1, a novel BAI1-binding protein. Brain Res Mol Brain Res 2001; 87:223-37.
31. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, Kharbanda S, Reimer C, Manfredi M, Dickerson WM, Kalluri R. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem 2001; 276:31959-68.
32. Saiki I, Iida J, Murata J, Ogawa R, Nishi N, Sugimura K, Tokura S, Azuma I. Inhibition of the metastasis of murine malignant melanoma by synthetic polymeric peptides containing core sequences of cell-adhesive molecules. Cancer Res 1989; 49:3815-22.
33. Ren M, Wang S, Lin X, Xu J, Tao Z, Zhao W, Liu X. Structural modification and anti-tumor activity change of recombinant human endostatin. Chin J Biochem Mol Biol 2005; 21:45-51.
34. Cheng HC, Yeh SI, Tsao YP, Kuo PC. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis. Mol Vis 2007; 13:2344-52.
35. Pan X, Wang Y, Zhang M, Pan W, Qi Z, Cao G. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on antiangiogenesis. World J Gastroenterol 2004; 10:1409-14.
36. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson Welsh L, Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998; 95:14389-94.
37. Saita N, Fujiwara N, Yano I, Soejima K, Kobayashi K. Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 2000; 68:5991-7.
38. Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998; 188:1039-46.
39. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003; 93:321-9.
40. Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112:806-16.
41. Noma H, Funatsu H, Mimura T, Shimada K. Increase of aqueous inflammatory factors in macular edema with branch retinal vein occlusion: a case control study. J Inflamm (Lond)
42. Kook H, Ahn KY, Lee SE, Na HS, Kim KK. Nitric oxidedependent cytoskeletal changes and inhibition of endothelial cell migration contribute to the suppression of angiogenesis by RAD50 gene transfer. FEBS Lett 2003; 553:56-62.
43. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M, Granger HJ, Chiarugi V, Ramponi G. Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 1999; 263:340-5.
44. Li XP, Li CY, Li X, Ding Y, Chan LL, Yang PH, Li G, Liu X, Lin JS, Wang J, He M, Kung HF, Lin MC, Peng Y. Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin. Mol Cancer Ther 2006; 5:1290-8.
45. Sipola A, Nelo K, Hautala T, Ilvesaro J, Tuukkanen J. Endostatin inhibits VEGF-A induced osteoclastic bone resorption in vitro. BMC Musculoskelet Disord 2006; 7:56.
46. Su Z, Wu X, Feng Y, Ding C, Xiao Y, Cai L, Feng W, Li X. High level expression of human endostatin in Pichia pastoris using a synthetic gene construct. Appl Microbiol Biotechnol 2007; 73:1355-62.
47. Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J, D'Amato RJ, Kuo C, Adamis AP. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci 2001; 42:1975-9.
48. Dannowski H, Bednarz J, Reszka R, Engelmann K, Pleyer U. Lipid-mediated gene transfer of acidic fibroblast growth factor into human corneal endothelial cells. Exp Eye Res 2005; 80:93-101.
49. Nguyen TH, Murakami A, Fujiki K, Kanai A. Transferrinpolyethylenimine conjugate, FuGENE6 and TransIT-LT as nonviral vectors for gene transfer to the corneal endothelium. Jpn J Ophthalmol 2002; 46:140-6.